Diagnostic performance of target vs. vessel μFR in stable coronary artery disease

稳定型冠状动脉疾病中靶血管μFR的诊断性能

阅读:2

Abstract

BACKGROUND: We aim to compare with the diagnostic performance of target-position quantitative flow ratio derived from Murray Law (target-μFR) and vessel quantitative flow ratio derived from Murray Law (vessel-μFR) using the fractional flow reserve (FFR) as reference standard. This study may provide more evidence for the novel clinical usage of target-μFR in the diagnosis of coronary artery disease. METHODS: Six hundreds and fifty-six patients (685 lesions) with known or suspected coronary artery disease were screened for this retrospective analysis between January 2021 to March 2023. A total of 161 patients (190 lesions) underwent quantitative coronary angiography and FFR evaluations. In the final analysis, 137 patients (146 lesions) were included in this study. Both of target-μFR and vessel-μFR were compared the diagnostic performance using the FFR ≤ 0.80 as the reference standard. RESULTS: Both target-μFR (R = 0.84) and vessel-μFR (R = 0.83) demonstrated a strong correlation with FFR, and both methods showed great agreement with FFR. The area under the receiver operating characteristic curve was 0.937 for target-μFR and 0.936 for vessel-μFR in predicting FFR ≤ 0.80. FFR ≤ 0.80 were predicted with high sensitivity (86.44%) and specificity (88.51%) using the pre-defined cutt-off of 0.80 for target-μFR. A good diagnostic performance (sensitivity 92.98% and specificity 91.01%) was also demonstrated by vessel-μFR which the pre-defined cutt-off was 0.80. CONCLUSION: The target-μFR has the similar diagnostic performance with vessel-μFR. The accuracy of μFR does not seem to be affected by the selection of the measurement point. Both of the virtual models have been validated as computational tools for diagnosing ischemia and are instrumental in aiding clinical decision-making.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。